Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-14

Clinical Trial Update: Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating etanercept in three subtypes of juvenile arthritis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etanercept (etanercept)

Snippet

Sponsor: Pfizer | Conditions: Juvenile Idiopahtic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-11-14